1 unchanged sentence
Market Information
−Removed: Our common stock is traded on the Nasdaq Global Select Market under the symbol “XLO”.
−Removed: Trading of our common stock commenced on October 22, 2021, following the completion of our initial public offering, or IPO.
+Added: Our common stock is traded on the Nasdaq Global Select Market under the symbol “XLO.” Trading of our common stock commenced on October 22, 2021, following the completion of our initial public offering, or IPO.
Prior to that date, there was no public market for our common stock.
−Removed: As of February 15, 2023, there were 58 holders of record of our common stock.
+Added: As of March 25, 2024, there were 35 holders of record of our common stock.
This number does not include beneficial owners whose shares are held in street name.
3 unchanged sentences
Any future determination to pay cash dividends will be at the discretion of our board of directors, and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as our board of directors deems relevant.
−Removed: Use of Proceeds from Initial Public Offering of Common Stock
−Removed: On October 26, 2021, we closed our IPO and issued and sold an aggregate of 7,353,000 shares of our common stock at a public offering price of $16.00 per share, and on November 1, 2021, we sold an additional 766,106 shares of common stock at a public offering price of $16.00 per share pursuant to the partial exercise by the underwriters of their option to purchase additional shares.
−Removed: The offer and sale of the shares of common stock in our IPO was registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No.
−Removed: 333-259973), which was declared effective by the SEC on October 21, 2021.
−Removed: Following the sale of the shares in connection with the partial exercise by the underwriters of their option, the offering terminated before all the securities registered in the registration statement were sold.
−Removed: Morgan Stanley & Co.
−Removed: LLC, Cowen and Company LLC and Guggenheim Securities, LLC acted as joint book-running managers for our IPO, and Raymond James & Associates, Inc.
−Removed: acted as lead manager for our IPO.
−Removed: We received aggregate gross proceeds from our IPO, inclusive of the exercise by the underwriters of their option to purchase additional shares, of $129.9 million, or aggregate net proceeds of $116.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us.
−Removed: None of these expenses consisted of direct or indirect payments made by us to directors, officers or persons owning 10% or more of our common stock or to their associates, or to our affiliates.
−Removed: As of December 31, 2022, we estimate that we have used approximately $95.0 million of the net proceeds from our IPO.
−Removed: We maintain the unused net proceeds from the offering in cash and cash equivalents.
−Removed: In November 2022, we announced that we plan to continue to explore opportunities for strategic collaborations to advance XTX101 and that we do not plan to initiate an anti-PD-1/PD-L1 combination cohort in the Phase 1 clinical trial or initiate a Phase 2 clinical trial for XTX101 without a partner.
−Removed: Other than the foregoing, there has been no material change in the planned use of the net proceeds from our IPO, as described in our final prospectus filed with the SEC on October 22, 2021 pursuant to Rule 424(b)(4) under the Securities Act.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.